Literature DB >> 15036258

Tumour invasion and matrix metalloproteinases.

Myriam Polette1, Béatrice Nawrocki-Raby, Christine Gilles, Christine Clavel, Philippe Birembaut.   

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes which play a major role in tumour invasion. They are mainly produced by host stromal cells in most carcinomas and their expression implies a close co-operation between tumour and stromal cells. Increasing data also demonstrate that, in association with a process of epithelial-to-mesenchymal transition, many MMPs can be expressed by tumour cell themselves. Their most well-known role is the degradation of extra-cellular matrix macromolecules which in turn may regulate tumour invasion in some conditions. This ECM degradation generates some matrikins which are also implicated in tumour invasion and angiogenesis. Moreover, MMPs are also implicated in the degradation of cell adhesion molecules and release and activation of growth factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036258     DOI: 10.1016/j.critrevonc.2003.10.008

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  58 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

Authors:  Rainer Kuefer; Kathleen C Day; Celina G Kleer; Michael S Sabel; Matthias D Hofer; Sooryanarayana Varambally; Christoph S Zorn; Arul M Chinnaiyan; Mark A Rubin; Mark L Day
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

3.  Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases.

Authors:  K A Paschos; D Canovas; N C Bird
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

4.  Transient mechanical strain promotes the maturation of invadopodia and enhances cancer cell invasion in vitro.

Authors:  Alexander N Gasparski; Snehal Ozarkar; Karen A Beningo
Journal:  J Cell Sci       Date:  2017-04-26       Impact factor: 5.285

5.  Activation of G protein coupled estrogen receptor (GPER) promotes the migration of renal cell carcinoma via the PI3K/AKT/MMP-9 signals.

Authors:  Bao-Zhang Guan; Rui-Ling Yan; Jian-Wei Huang; Fo-Lan Li; Ying-Xue Zhong; Yu Chen; Fan-Na Liu; Bo Hu; Si-Bo Huang; Liang-Hong Yin
Journal:  Cell Adh Migr       Date:  2018-01-29       Impact factor: 3.405

6.  CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.

Authors:  Erica L Johnson; Rajesh Singh; Shailesh Singh; Crystal M Johnson-Holiday; William E Grizzle; Edward E Partridge; James W Lillard
Journal:  World J Surg Oncol       Date:  2010-07-22       Impact factor: 2.754

Review 7.  miRNAs regulate expression and function of extracellular matrix molecules.

Authors:  Zina Jeyapalan Rutnam; Thomas N Wight; Burton B Yang
Journal:  Matrix Biol       Date:  2012-11-15       Impact factor: 11.583

8.  High expression of BAG3 predicts a poor prognosis in human medulloblastoma.

Authors:  Dong Yang; Ji Zhou; Hao Wang; Yutao Wang; Ge Yang; Yundong Zhang
Journal:  Tumour Biol       Date:  2016-07-25

9.  LRP1 regulates remodeling of the extracellular matrix by fibroblasts.

Authors:  Alban Gaultier; Margaret Hollister; Irene Reynolds; En-hui Hsieh; Steven L Gonias
Journal:  Matrix Biol       Date:  2009-08-20       Impact factor: 11.583

10.  BAG3 regulates epithelial-mesenchymal transition and angiogenesis in human hepatocellular carcinoma.

Authors:  Heng Xiao; Shaobing Cheng; Rongliang Tong; Zheng Lv; Chaofeng Ding; Chengli Du; Haiyang Xie; Lin Zhou; Jian Wu; Shusen Zheng
Journal:  Lab Invest       Date:  2013-12-23       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.